Clinical Trials
22 trialsNCT07625527 2026-06-04
Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?
Tianjin Medical University Second Hospital
Phase 2 Not yet recruiting
NCT04375813 2026-06-03
eRapa
The University of Texas Health Science Center at San Antonio
Phase 2 Active not recruiting
NCT06833073 2026-05-28
INTerpath-011
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT06972615 2026-05-28
Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy
BLATAM
Phase 2 Recruiting
NCT06995677 2026-05-20
SURF302
Tyra Biosciences, Inc
Phase 2 Recruiting
NCT05951179 2026-05-18
ADVANCED-2
Protara Therapeutics
Phase 2 Recruiting
NCT06733363 2026-05-08
A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT05796375 2026-05-04
ReplaceCysto
White River Junction Veterans Affairs Medical Center
Phase 2 Recruiting
NCT07283835 2026-04-23
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Lepu Biopharma Co., Ltd.
Phase 2 Recruiting
NCT04917809 2026-04-22
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT07322263 2026-04-17
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
University of Iowa
Phase 2 Recruiting
NCT06503614 2026-04-08
ENHANCE
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT04172675 2026-02-24
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Janssen Research & Development, LLC
Phase 2 Completed
NCT05327647 2025-12-18
BicaBCa
CHU de Quebec-Universite Laval
Phase 2 Recruiting
NCT03945162 2025-11-24
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Theralase® Technologies Inc.
Phase 2 Recruiting
NCT04386746 2025-11-17
GEMDOCE
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT06829823 2025-10-16
Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer
ImmunityBio, Inc.
Phase 2 Not yet recruiting
NCT03914794 2025-10-03
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT07189793 2025-09-24
OHAI-NMIBC-01
First Affiliated Hospital of Wenzhou Medical University
Phase 2 Not yet recruiting
NCT07100184 2025-08-03
RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients
Peking University First Hospital
Phase 2 Not yet recruiting
NCT06663137 2025-06-13
HGNMIBC
Relmada Therapeutics, Inc.
Phase 2 Recruiting
NCT07019220 2025-06-13
COBRA
Medical University of Vienna
Phase 2 Recruiting